"Sequencing of ramucirumab (ram) and immune checkpoint inhibitors (ICIs) in platinum (Pt)-treated real-world patients (pts) with advanced non-small cell lung cancer (aNSCLC)."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Sequencing of ramucirumab (ram) and immune checkpoint inhibitors (ICIs) in platinum (Pt)-treated real-world patients (pts) with advanced non-small cell lung cancer (aNSCLC).

e21209Background: Ram+docetaxel & ICIs are FDA-approved for aNSCLC pts failing Pt therapy. Optimal sequencing of these regimens is unknown. The study objective was to evaluate sequence patterns and... Click to show full abstract

Keywords: immune checkpoint; checkpoint inhibitors; ram immune; sequencing ramucirumab; ramucirumab ram; ram

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended